Ejection fraction (EF) <55% or the lower limit of normal of the institutional standard will be excluded. Only in cases where the Investigator (or the treating physician or both) suspects cardiac disease with negative effect on the EF will the EF be measured during screening using an appropriate method according to local standards to confirm eligibility (e.g., echocardiogram [ECHO], multi-gated acquisition scan [MUGA]). A historic measurement of EF no older than 6 months prior to first administration of study drug can be accepted provided that there is clinical evidence that the EF value has not worsened since this measurement in the opinion of the Investigator or of the treating physician or both.
Have a 2-dimensional (2D) echocardiogram with left ventricular ejection fraction = or > 45% in order to receive epirubicin; subjects with inadequate ejection fraction (EF) or other contraindication can proceed on study without the use of epirubicin
Have adequate cardiac function as assessed by echocardiogram, with an ejection fraction (EF) > 45%
Significant cardiovascular abnormalities as defined by any one of the following: congestive heart failure, clinically significant hypotension, symptomatic coronary artery disease, or a documented ejection fraction of < 45%; any patient with an ejection fraction (EF) of 45-49% must receive clearance by a cardiologist to be eligible for the trial
Cardiac ejection fraction (EF) < 40%
Cardiac ejection fraction (EF) >= 45% by 2-dimensional echocardiogram (2D-ECHO) within 3 months of study entry (or within 1 month if received chemotherapy within the past 3 months)
Left ventricular ejection fraction (EF) >= 45%
Left ventricular ejection fraction (EF) >= 45% with no uncontrolled arrhythmias or symptomatic heart disease
Normal left ventricular ejection fraction, as defined by ejection fraction (EF) >= 50%
Adequate cardiac reserve (ejection fraction [EF] >= 50%)
Ejection fraction (EF) by multigated acquisition scan (MUGA) or 2-dimensional (2-D) echocardiogram within institution normal limits; in case of low EF, the subject may remain eligible after a stress echocardiogram is performed if the EF is more than 35% and if the increase in EF with stress is estimated at 10% or more
Ejection fraction (EF) by multiple gated acquisition scan (MUGA) or 2-dimensional (D) echocardiogram within institution normal limits; in case of low EF, the subject may remain eligible after a stress echocardiogram is performed if the EF is more than 35% and if the increase in EF with stress is estimated at 10% or more
Patients with ECHO EF >= 45% within 28 days prior to registration
No Symptomatic Congestive Heart Failure (Ejection Fraction EF ? 50%)
Left ventricular ejection fraction (EF) >= 50%
Ejection fraction (EF) >= 50% and no uncontrolled angina, symptomatic ventricular arrhythmias, or electrocardiogram (ECG) evidence of active ischemia
Ejection fraction (EF) of < 40%, myocardial infarction (MI) within past 3 months, uncontrolled angina, severe uncontrolled ventricular arrythmias, or ECG evidence of acute ischemia.
Left ventricular ejection fraction (EF) >= 45% with no uncontrolled arrythmias or symptomatic heart disease
Ejection fraction (EF) < 35% or uncontrolled cardiac failure
Ejection fraction (EF) >= 35%
Patients with poor cardiac function defined as an ejection fraction (EF) < 40% are excluded
Left ventricular ejection fraction (EF) < 50%
Left ventricular EF > 40%.
No history of serious cardiac arrhythmia or ejection fraction (EF) < 50%
Known heart failure (ejection fraction [EF] < 40%)
Left ventricular ejection fraction (EF) < 50% at baseline
Cardiac ejection fraction (EF) >= 45% by 2-dimensional echocardiogram (2D-Echo)
Ejection fraction (EF) >= 45%
Congestive heart failure or documented cardiomyopathy with an EF ?50%, provided that EF ?35% or,